PL3512506T3 - Zastosowanie pridopidyny w leczeniu zespołu retta - Google Patents

Zastosowanie pridopidyny w leczeniu zespołu retta

Info

Publication number
PL3512506T3
PL3512506T3 PL17851614T PL17851614T PL3512506T3 PL 3512506 T3 PL3512506 T3 PL 3512506T3 PL 17851614 T PL17851614 T PL 17851614T PL 17851614 T PL17851614 T PL 17851614T PL 3512506 T3 PL3512506 T3 PL 3512506T3
Authority
PL
Poland
Prior art keywords
pridopidine
rett syndrome
treating rett
treating
syndrome
Prior art date
Application number
PL17851614T
Other languages
English (en)
Polish (pl)
Inventor
Michal Geva
Ralph Laufer
Michael Hayden
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL3512506T3 publication Critical patent/PL3512506T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PL17851614T 2016-09-16 2017-09-15 Zastosowanie pridopidyny w leczeniu zespołu retta PL3512506T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16
EP17851614.2A EP3512506B1 (en) 2016-09-16 2017-09-15 Use of pridopidine for treating rett syndrome
PCT/US2017/051803 WO2018053280A1 (en) 2016-09-16 2017-09-15 Use of pridopidine for treating rett syndrome

Publications (1)

Publication Number Publication Date
PL3512506T3 true PL3512506T3 (pl) 2022-05-30

Family

ID=61619744

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17851614T PL3512506T3 (pl) 2016-09-16 2017-09-15 Zastosowanie pridopidyny w leczeniu zespołu retta
PL22150695.9T PL4005570T3 (pl) 2016-09-16 2017-09-15 Pridopidyna do zastosowania w leczeniu zespołu retta

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL22150695.9T PL4005570T3 (pl) 2016-09-16 2017-09-15 Pridopidyna do zastosowania w leczeniu zespołu retta

Country Status (13)

Country Link
EP (2) EP3512506B1 (cg-RX-API-DMAC7.html)
JP (1) JP6977029B2 (cg-RX-API-DMAC7.html)
CN (1) CN109982686A (cg-RX-API-DMAC7.html)
AU (1) AU2017326013B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019005040A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036984C (cg-RX-API-DMAC7.html)
DK (2) DK4005570T3 (cg-RX-API-DMAC7.html)
ES (2) ES2909557T3 (cg-RX-API-DMAC7.html)
HU (1) HUE058314T2 (cg-RX-API-DMAC7.html)
IL (1) IL265342B2 (cg-RX-API-DMAC7.html)
MX (1) MX388845B (cg-RX-API-DMAC7.html)
PL (2) PL3512506T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018053280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EP3503890B1 (en) 2016-08-24 2024-12-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating dystonias
MX390627B (es) 2016-08-24 2025-03-21 Prilenia Neurotherapeutics Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CN109982686A (zh) 2016-09-16 2019-07-05 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗rett综合征的用途
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
BR112021015346A2 (pt) 2019-02-04 2021-10-05 Prilenia Neurotherapeutics Ltd. Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
JP6949487B2 (ja) * 2014-01-22 2021-10-13 プリレニア・ニューロセラピューティクス・エルティーディーPrilenia Neurotherapeutics Ltd プリドピジンの調節放出製剤
EP4282479A3 (en) * 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
CN109982686A (zh) 2016-09-16 2019-07-05 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗rett综合征的用途

Also Published As

Publication number Publication date
CN109982686A (zh) 2019-07-05
JP2019532926A (ja) 2019-11-14
MX388845B (es) 2025-03-20
ES2909557T3 (es) 2022-05-09
ES2986807T3 (es) 2024-11-12
PL4005570T3 (pl) 2024-09-23
IL265342A (en) 2019-05-30
AU2017326013B2 (en) 2020-12-24
DK3512506T3 (da) 2022-04-19
DK4005570T3 (da) 2024-08-19
AU2017326013A1 (en) 2019-04-11
EP3512506A1 (en) 2019-07-24
EP4005570A1 (en) 2022-06-01
MX2019003069A (es) 2019-09-02
CA3036984C (en) 2023-07-18
HUE058314T2 (hu) 2022-07-28
JP6977029B2 (ja) 2021-12-08
IL265342B2 (en) 2023-06-01
WO2018053280A1 (en) 2018-03-22
CA3036984A1 (en) 2018-03-22
EP3512506A4 (en) 2020-05-27
EP4005570B1 (en) 2024-05-15
EP3512506B1 (en) 2022-01-26
BR112019005040A2 (pt) 2019-07-16

Similar Documents

Publication Publication Date Title
IL259560A (en) Inhibitors of the menin-mll interaction
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
ZA201606610B (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
IL265342A (en) Use of pridofidine for the treatment of Rett syndrome
IL247515A0 (en) Snekribirock for the treatment of leprosy
ZA201706257B (en) Treatment of wood
IL257061A (en) Inhibitors of ezh2
IL259856A (en) A preparation for the treatment of Crigler-Najjar syndrome
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
PT3122349T (pt) Composições para o tratamento da autodigestão
IL251350A0 (en) Treatment of Rett syndrome
GB201412010D0 (en) Treatment of hypertransaminasemia
IL262547A (en) Methods and compositions for treatment of rett syndrome
HK40009961A (en) Use of pridopidine for treating rett syndrome
EP3122187A4 (en) Treatment of rett syndrome